- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07949838
Efficacy and Safety of Cyclophosphamide in Pediatric Patients With Steroid-Refractory Acute Disseminated Encephalomyelitis (ADEM) (CYC-ADEM-Peds)
A Randomized, Open-Label, Comparative Clinical Trial Evaluating the Efficacy and Safety of Cyclophosphamide Versus Intravenous Immunoglobulin (IVIG) in Pediatric Patients With Steroid-Refractory Acute Disseminated Encephalomyelitis
Acute Disseminated Encephalomyelitis (ADEM) is a severe, immune-mediated demyelinating disease of the central nervous system predominantly affecting the pediatric population. Although high-dose intravenous corticosteroids (such as methylprednisolone) represent standard first-line therapy, a subset of clinical cases fails to achieve adequate clinical response, carrying high risks of persistent neurological disability, neurodevelopmental sequelae, or fulminant deterioration.
This randomized, open-label trial evaluates the clinical efficacy, neuroimaging outcomes, and safety profile of intravenous cyclophosphamide pulse therapy compared with intravenous immunoglobulin (IVIG) as a rescue modality in pediatric patients under 14 years of age with steroid-refractory ADEM. Eligible participants are allocated using a computer-based random number generator. Enrolled patients are prospectively monitored for neurological recovery, functional disability using the pediatric Liverpool Outcome Score (LOS), radiological resolution on neuroimaging (MRI), overall survival, and treatment-emergent adverse events.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Acute Disseminated Encephalomyelitis (ADEM) is an immune-mediated demyelinating inflammatory disorder of the central nervous system predominantly affecting pediatric patients. While high-dose intravenous corticosteroids (such as methylprednisolone) serve as the standard first-line treatment, a clinical subset of patients fails to respond, presenting persistent neurological deficits, neurodevelopmental sequelae, or fulminant clinical deterioration.
This prospective, randomized, open-label comparative clinical trial is designed to evaluate the therapeutic efficacy, neuroimaging resolution, and safety profile of intravenous cyclophosphamide pulse therapy compared with intravenous immunoglobulin (IVIG) as a standard second-line immunomodulatory therapy in pediatric patients under 14 years of age with steroid-refractory ADEM.
Eligible participants (a total of 30 pediatric patients) are randomized in a 1:1 ratio using a computer-generated random number sequence into two equal treatment arms: 15 patients in the experimental arm receive intravenous cyclophosphamide pulse therapy (500 mg/m2) combined with intensive hydration and Mesna uroprotection to prevent hemorrhagic cystitis, while 15 patients in the active comparator arm receive standard intravenous immunoglobulin (IVIG) immunomodulatory therapy (2 g/kg).
Longitudinal monitoring is performed across both cohorts to assess neurological functional recovery and disability using the pediatric-validated Liverpool Outcome Score (LOS), radiological clearance on brain and spine MRI, overall survival up to 24 months, and the active surveillance of treatment-emergent adverse events.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Fatima Amer, MD
- Phone Number: +963 966494768
- Email: Fatema.amer@damascusuniversity.edu.sy
Study Locations
-
-
-
Damascus, Syria
- Recruiting
- Children's University Hospital
-
Contact:
- Fatima Amer, MD
- Phone Number: +963 966494768
- Email: Fatema.amer@damascusuniversity.edu.sy
-
Principal Investigator:
- Fatima Amer, MD
-
Principal Investigator:
- Sameer Baqla, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Pediatric patients younger than 14 years of age (< 14 years) at clinical presentation.
- Confirmed diagnosis of Acute Disseminated Encephalomyelitis (ADEM) fulfilling the consensus criteria defined by the International Pediatric Multiple Sclerosis Study Group (IPMSSG).
- Steroid-refractory clinical status, defined as active disease persistence, neurological deterioration, or absence of significant functional improvement following a 3-5 day course of high-dose intravenous methylprednisolone pulse therapy (20-30 mg/kg/day).
- Intact baseline renal function (serum creatinine and BUN within age-adjusted normal physiological ranges).
- Intact baseline hepatic function (AST, ALT, and bilirubin within acceptable limits).
- Absence of active systemic sepsis, bacteremia, or acute uncontrolled systemic infection at baseline.
- Formal written informed consent obtained from parents or legal guardians.
Exclusion Criteria:
- Patients aged 14 years and older (≥ 14.0 years).
- Pre-existing significant renal insufficiency, acute kidney injury, or chronic renal disease.
- Pre-existing hepatic failure, cirrhosis, or acute severe hepatic injury.
- Active systemic sepsis or uncontrolled severe systemic infection.
- Pre-existing severe bone marrow suppression (baseline absolute neutrophil count ANC ≤ 1500/mm³ or platelet count < 50,000/mm³).
- History of known hypersensitivity to cyclophosphamide, Mesna, or immunoglobulin preparations.
- Alternative neuroinflammatory or metabolic diagnosis confirmed.
- Refusal of parents or legal guardians to grant written informed consent.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Cyclophosphamide IV
Fifteen pediatric patients (<14 years) with steroid-refractory ADEM randomized to this experimental group will receive intravenous cyclophosphamide pulse therapy as rescue treatment. |
Administered as intravenous pulse therapy at a dosage of 500 mg/m² body surface area. Delivered with intensive pre- and post-hydration protocols along with Mesna (2-mercaptoethane sulfonate sodium) uroprotection to mitigate acrolein-induced hemorrhagic cystitis. |
|
Active Comparator: Intravenous Immunoglobulin (IVIG)
Fifteen pediatric patients (<14 years) with steroid-refractory ADEM randomized to this active comparator group receive intravenous immunoglobulin (IVIG) as a standard second-line immunomodulatory therapy for ADEM. |
Administered at a total immunomodulatory dose of 2 g/kg body weight, infused according to standard pediatric institutional protocols (either 1 g/kg/day for 2 consecutive days or 400 mg/kg/day over 5 consecutive days), under continuous hemodynamic monitoring. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Neurological Functional Outcome and Disability Assessment by Liverpool Outcome Score (LOS)
Time Frame: Assessed at hospital discharge, and longitudinally at 2, 4, and 12 weeks post-treatment initiation.
|
Evaluation of functional recovery and post-encephalitic neurological sequelae using the pediatric-validated Liverpool Outcome Score (LOS). The LOS stratifies pediatric neuro-outcomes into 5 distinct categories:
|
Assessed at hospital discharge, and longitudinally at 2, 4, and 12 weeks post-treatment initiation.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Radiological Resolution on Neuroimaging (Brain & Spine MRI)
Time Frame: Assessed at 2,4 and 12 weeks post-treatment initiation.
|
Quantitative and qualitative reduction or total resolution of hyperintense demyelinating lesions on T2/FLAIR sequences, resolution of contrast enhancement, and absence of new active or demyelinating lesions. |
Assessed at 2,4 and 12 weeks post-treatment initiation.
|
|
Overall Survival and All-Cause Mortality Rate
Time Frame: Up to 24 months
|
Proportion of pediatric patients surviving without fatal disease complications or fulminant progression throughout the study observation window. |
Up to 24 months
|
|
Treatment-Emergent Adverse Events & Tolerability
Time Frame: Inpatient stay and longitudinally at 1, 2, and 12 weeks post-treatment initiation.
|
Incidence and severity of adverse drug reactions including bone marrow suppression (CBC) and hemorrhagic cystitis (Urinalysis) |
Inpatient stay and longitudinally at 1, 2, and 12 weeks post-treatment initiation.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Fatima Amer, MD, Department of Pediatric Neurology, Faculty of Medicine, Damascus University, Damascus, Syrian Arab Republic
- Study Director: Sameer Baqla, PhD, Department of Pediatric Neurology, Faculty of Medicine, Damascus University, Damascus, Syrian Arab Republic
- Study Director: Sally Kadoura, PhD, Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Damascus University, Damascus, Syrian Arab Republic
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Post-Infectious Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Pathologic Processes
- Chronic Disease
- Disease Attributes
- Autoimmune Diseases
- Immune System Diseases
- Autoimmune Diseases of the Nervous System
- Demyelinating Diseases
- Leukoencephalopathies
- Pathological Conditions, Signs and Symptoms
- Demyelinating Autoimmune Diseases, CNS
- Encephalomyelitis, Acute Disseminated
- Amino Acids, Peptides, and Proteins
- Proteins
- Organic Chemicals
- Hydrocarbons
- Antibodies
- Immunoglobulins
- Immunoproteins
- Blood Proteins
- Serum Globulins
- Globulins
- Phosphoramide Mustards
- Nitrogen Mustard Compounds
- Mustard Compounds
- Hydrocarbons, Halogenated
- Phosphoramides
- Organophosphorus Compounds
- Immunoglobulin Isotypes
- Immunoglobulin G
- Cyclophosphamide
- Immunoglobulins, Intravenous
Other Study ID Numbers
- MD-051124-349
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.